Amgen to Acquire Chemocentryx for ~$4B

Share this


Amgen to Acquire Chemocentryx for ~$4B


  • Amgen to acquire ChemoCentryx for $52/share in cash at total enterprise value of ~$3.7B representing a premium of ~116% to the last close date. The transaction is expected to close in Q4’22
  • The acquisition will enable Amgen to add its decades-long leadership in inflammation & nephrology with Tavneos which focused on developing treatments for autoimmune diseases, inflammatory disorders & cancer. ChemoCentryx has 3 early-stage drug products targeting chemoattractant receptors in other inflammatory diseases & oral checkpoint inhibitor for cancer
  • Tavneos was approved in the US for sev. active ANCA-associated vasculitis in combination with standard therapy & was also approved outside of the US incl. the EU & Japan. Amgen’s portfolio includes Otezla, Enbrel, Tezspire, Amgevita, Riabni & Avsola

Ref: Amgen | Image: Chemocentryx

Click here to­ read the full press release 


Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions